Roche

Exelixis bounces back with new prostate cancer data

Announces encouraging results after initial trial fail. Exelixis has announced that its lead drug cabozantinib, in combination with Roche’s Tecentriq, demonstrated encouraging results in a phase 1 prostate cancer trial.

Double blow to amyloid drug hopes as Roche, Lilly trial fails

The two investigational candidates were unable to show benefit. A clinical trial of Roche and Eli Lilly anti-amyloid drugs in inherited forms of Alzheimer’s disease has ended in failure, ... At the same time, another arm of the study testing Roche’s

Skyrizi, Rinvoq help AbbVie weather Humira slowdown

venetoclax) that keeps it on course to meet AbbVie and partner Roche’s blockbuster aspirations for the drug.

Roche builds case for SMA drug risdiplam as FDA verdict nears

Outcome of FDA review due by 24 May. Roche has revealed new efficacy data for its spinal muscular atrophy drug risdiplam as it waits for the outcome of a review by ... part 2, which Roche said “represents a broad, real-world spectrum of people living

Biogen triumphs over Mylan’s Tecfidera patent challenge

language. Although the patent dispute is an overwhelming win, Biogen has been facing other challenges in the MS market from new treatments, including Novartis’ newly-approved Mayzent and Roche’s Ocrevus.

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]